KTTA PASITHEA THERAPEUTICS CORP revenue, earnings and financials
For the quarter ended June 30, 2026, PASITHEA THERAPEUTICS CORP reported revenue of n/a, net income of −$5.27M and diluted EPS of −$0.16; for the fiscal year ended December 2025 revenue was n/a.
KTTA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$20.9M, net income −$20.4M (margin n/a), EPS −$2.91
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$14.2M, net income −$13.9M (margin n/a), EPS −$12.69
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$16.0M, net income −$16.0M (margin n/a), EPS −$0.42
- Fiscal year ended Dec 2022: revenue $487K, gross profit n/a, operating income −$12.6M, net income −$13.9M (margin -2864.3%), EPS −$1.76
- Fiscal year ended Dec 2021: revenue $15.1K, gross profit −$2.21K, operating income −$4.51M, net income −$2.17M (margin -14430.5%), EPS −$0.21
KTTA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$5.27M, EPS −$0.16
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.87M, EPS −$0.12
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$10.1M, EPS −$0.23
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.04M, EPS −$0.41
- Quarter ended Jun 30, 2025: revenue n/a, net income −$3.72M, EPS −$0.66
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.56M, EPS −$1.61
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$3.18M, EPS −$2.41
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.00M, EPS −$2.87
- Quarter ended Jun 30, 2024: revenue n/a, net income −$3.87M, EPS −$3.71
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.86M, EPS −$3.70
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.05M, EPS −$0.40
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.61M, EPS $0.00
- Quarter ended Jun 30, 2023: revenue n/a, net income −$3.76M, EPS −$0.01
- Quarter ended Mar 31, 2023: revenue n/a, net income −$3.54M, EPS −$0.01
- Quarter ended Dec 31, 2022 (from the annual report): revenue $241K, net income −$5.12M, EPS −$1.72
- Quarter ended Sep 30, 2022: revenue $219K, net income −$4.59M, EPS −$0.01
- Quarter ended Jun 30, 2022: revenue $13.6K, net income −$2.66M, EPS −$0.02
- Quarter ended Mar 31, 2022: revenue $13.7K, net income −$1.57M, EPS −$0.01
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $630K, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.53M, EPS −$0.17
KTTA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$15.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$13.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow n/a, share buybacks $3.73M
- Fiscal year ended Dec 2022: operating cash flow −$14.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$3.17M, share buybacks n/a
KTTA balance sheet
- Jun 30, 2026: cash $45.7M, total assets $51.7M, total liabilities $1.87M, shareholders' equity $49.8M
- Mar 31, 2026: cash $50.4M, total assets $56.4M, total liabilities $1.54M, shareholders' equity $54.8M
- Dec 31, 2025: cash $55.2M, total assets $60.2M, total liabilities $5.02M, shareholders' equity $55.2M
- Sep 30, 2025: cash $4.12M, total assets $13.6M, total liabilities $1.42M, shareholders' equity $12.2M
- Jun 30, 2025: cash $7.22M, total assets $17.0M, total liabilities $1.83M, shareholders' equity $15.2M
- Mar 31, 2025: cash $5.34M, total assets $14.7M, total liabilities $1.68M, shareholders' equity $13.0M
- Dec 31, 2024: cash $6.92M, total assets $16.1M, total liabilities $1.28M, shareholders' equity $14.8M
- Sep 30, 2024: cash $9.36M, total assets $18.6M, total liabilities $824K, shareholders' equity $17.8M
Is KTTA profitable?
No. PASITHEA THERAPEUTICS CORP lost $21.3M over the last four quarters.
What is KTTA's EPS?
Diluted earnings per share over the last four quarters were −$0.92; −$0.16 in the latest quarter.